Core 1 - Research Technology Core

核心1 - 研究技术核心

• 批准号: 10249211
• 负责人: Gregg Joshua Silverman
• 金额: $ 16.23万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-22 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10249211
• 关键词: 16S ribosomal RNA sequencing; Antibodies; Antibody Response; Antigens; Apoptosis; Area; Autoantibodies; Autoimmune Diseases; Autoimmunity; B cell repertoire; B-Lymphocytes; Bacteria; Biological Assay; Cell Separation; Cells; Clinical; Clone Cells; Complementary DNA; Core Facility; Custom; Diagnostic; Disease; Ensure; Flow Cytometry; Genes; Human; Immune Tolerance; Immunoglobulin A; Individual; Inflammatory; Intestines; Investigation; Libraries; Lupus; Magnetism; Methods; Molecular Profiling; Mus; Pathogenesis; Pathway interactions; Phase; Process; Research; Ribosomal RNA; Role; Sampling; Secretory Immunoglobulin A; Serum; Services; Standardization; Surveys; Technology; Transcript; Vendor; antigen binding; commensal bacteria; design; gut bacteria; gut microbiome; microbiome; microbiome analysis; natural antibodies; next generation sequencing; pre-clinical; programs; response; systemic autoimmune disease

ABSTRACT In this program on lupus pathogenesis, we seek to understand the pathways that drive autoimmunity. The Research Technology Core (Core 1) is dedicated to providing standardized means for the study of these B cell and antibody responses, and for investigations of the host relationship with commensal bacteria in the gut. The Core will provide services that have customized to the needs of each of the Projects. Through centralization of these facilities, we will provide services that provide economies of scale and efficiency. These methods are state-of-the-art and are otherwise not available from NYU Core facilities or from commercial vendors. The Research Technology Core will perform already validated assays in four areas: i) Autoantibody surveys from serum and fecal samples. ii) Isolation of fecal bacteria coated in the bowel by endogenously produced IgA. iii) Microbiome analyses by 16S rRNA methods by Next Generation Sequencing. iv) Large-scale BCR transcript repertoire libraries. Herein, we will support studies for all three Projects of the contributions of specific antibody/B-cell clones from the initial breach of immune tolerance, and in the transition from preclinical to overt clinical disease, and during the later phase of ongoing disease process characterized by self-perpetuation of autoimmune disease.

摘要 在这个关于狼疮发病机制的节目中，我们试图了解驱动自身免疫的途径。这个 研究技术核心(核心1)致力于为这些B细胞的研究提供标准化手段 和抗体反应，以及调查宿主与肠道共生细菌的关系。 核心将提供为每个项目的需求量身定做的服务。穿过 将这些设施集中起来，我们将提供规模经济和效率高的服务。这些 方法是最先进的，否则不能从纽约大学核心设施或商业机构获得 卖家。 研究技术核心将在四个领域执行已经经过验证的分析： I)从血清和粪便样本中进行自身抗体调查。 Ii)通过内源性产生的免疫球蛋白A分离肠道内包被的粪便细菌。 3)下一代测序的16S rRNA方法分析微生物组。 4)大规模的BCR转录资料库。 在此，我们将支持对所有三个项目的研究，这些项目都是关于来自 最初对免疫耐受的破坏，以及从临床前疾病向临床显性疾病的过渡，以及 自身免疫性疾病正在进行的疾病过程的后期，以自身免疫性疾病的自我延续为特征。